Seven new Centres of Excellence for Regulatory Science and Innovation (CERSIs) are to receive funding up to £1 ($1.2) million each, to lead the way in safer, faster pathways for innovative medicines and devices. 

The centres will be funded by Innovate UK in partnership with the Medicines and Healthcare products Regulatory Agency (MHRA), Office for Life Sciences, and the Medical Research Council. 

They will be led by academic institutions, independent innovators, or regulatory leaders forming collaborative partnerships. 

The network of centres aims to improve healthcare by simplifying how treatments move from lab bench to patient bedside. By helping researchers and businesses address regulatory challenges and opportunities, the centres will help accelerate the delivery of pioneering treatments, ensuring patients benefit from cutting-edge innovations. 

The seven CERSIs

For the delivery of CERSIs, Innovate UK created the Regulatory Science and Innovation Networks (RSINs) competition, inviting experts from academia, industry, and charities to reimagine medical innovation pathways.   

Seventeen networks have received initial funding. Now, seven networks have been chosen to move into the Implementation Phase.  

The seven projects are:  

  • Digital Transformation of Medicines Development and Manufacturing, led by University of Strathclyde, to accelerate the adoption of digital tools in medicine development. 
  • The UK Regulatory Innovation Network for Advanced Therapies, led by Cell and Gene Therapy Catapult, to streamline regulation of Advanced Therapy Medicinal Products. 
  • Regulatory Science Empowering Innovation in Transformative Digital Health and AI, led by Brunel University, to safely maximise the potential of AI-powered healthcare solutions. 
  • Centre of Excellence on In-silico Regulatory Science and Innovation, led by University of Manchester, to integrate evidence from computational models into the regulatory process. 
  • Clinical Evaluation & Assessment for Regulation of Diagnostic tests, led by Psephos Ltd, to help create safe availability of diagnostic tests for patients. 
  • Centre of Excellence for Regulatory Science and Innovation in AI & Digital Health Technologies (CERSI-AI), led by University of Birmingham, to optimise the regulation of AI and digital healthcare technologies to ensure innovations are safe and effective for patients. 
  • Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics, led by University of Liverpool, to develop guidelines for using pharmacogenomics in practice, and attract further investment in this area. 

Ailsa Kennedy-Ballard, Deputy Director Innovation Programmes & Partnerships at Innovate UK, said: “Innovate UK is pleased to announce these seven new CERSIs, which represent a landmark in healthcare innovation regulation. Backed by up to £1 million each, they will drive safer pathways for groundbreaking medicines and devices, ensuring the UK remains at the forefront of global medical advancements. 

“By fostering collaboration between academia, business and regulators, these centres will pave the way for life-changing innovations to reach patients more swiftly and safely.”

Diana Spencer, Senior Digital Content Editor, DDW